SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is a monovalent vaccine composed of a recombinant, replicationincompetent human adenovirus type 26 vector that encodes a SARS-CoV-2 full-length spike (S) glycoprotein in a stabilised conformation. Following administration, the S glycoprotein of SARSCoV-2 is transiently expressed, stimulating both neutralising and other functional S-specific antibodies, as well as cellular immune responses directed against the S antigen, which may contribute to protection against COVID-19.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC Group | Classification | |
|---|---|---|
| J07BN | Covid-19 vaccines | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines |
| J07BN02 | J Antiinfectives for systemic use → J07 Vaccines → J07B Viral vaccines → J07BN Covid-19 vaccines | |
SARS-CoV-2 Spike glycoprotein (Ad26.COV2-S) is an active ingredient of these brands:
Estonia (EE)
France (FR)
Japan (JP)
Netherlands (NL)
Poland (PL)
South Africa (ZA)
Spain (ES)
Tunisia (TN)
Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.